论文部分内容阅读
目的探讨早期乳腺浸润性导管癌中microRNA-10b(mi R-10b)表达与临床指标及预后关系。方法采用原位分子杂交技术,检测305例中早期乳腺浸润性导管癌组织miR-10b表达,采用Pearson χ~2检验分析miR-10b表达在不同临床指标间的差异性;采用Spearman秩和相关分析早期乳腺浸润性导管癌中miR-10b、年龄、淋巴结、雌激素受体α(ERα)、孕激素受体(PR)及人类表皮生长因子受体2(HER-2)之间的相关性。采用Kaplan-Meier法计算累计无瘤生存时间,应用Log-rank检验比较miR-10b不同表达组间无瘤生存时间的差异。结果早期乳腺浸润性导管癌中miR-10b表达与年龄、肿瘤大小和复发转移,差异具有统计学意义(P<0.05);与月经状态、临床分期、化疗、放疗及内分泌治疗比较,差异无统计学意义(P>0.05)。miR-10b阳性表达与HER-2阳性表达呈正相关,差异有统计学意义(P<0.05)。miR-10b表达阴性中位无瘤生存时间较miR-10b表达阳性时间长,两者比较差异有统计学意义(P<0.05);淋巴结阴性时miR-10b阴性表达的中位无瘤生存时间较阳性表达长,两者比较差异有统计学意义(P<0.05);相反,miR-10b表达在淋巴结阳性中位无瘤生存时间无统计学意义(P>0.05)。结论 miR-10b表达水平与早期乳腺浸润性导管癌复发转移相关,特别在无淋巴结转移且miR-10b阳性表达组的中位无瘤生存时间短,预后差。miR-10b阳性表达是早期乳腺浸润性导管癌的预后因素。
Objective To investigate the relationship between miRNA-10b (mi R-10b) expression and prognosis in early breast invasive ductal carcinoma. Methods In situ hybridization was used to detect the expression of miR-10b in 305 patients with invasive ductal carcinoma of the breast in early stage. The Pearson χ ~ 2 test was used to analyze the difference of miR-10b expression between different clinical indicators. Spearman rank correlation analysis Correlation between miR-10b, age, lymph nodes, estrogen receptor alpha (ERa), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) in early invasive ductal carcinomas. The cumulative tumor-free survival time was calculated by Kaplan-Meier method. Log-rank test was used to compare the difference of tumor-free survival time between different expression groups of miR-10b. Results The expression of miR-10b in early breast invasive ductal carcinoma was significantly different from that in age, tumor size, recurrence and metastasis (P <0.05). There was no statistical difference between the expression of miR-10b and the status of menstruation, clinical stage, chemotherapy, radiotherapy and endocrine therapy Significance (P> 0.05). The positive expression of miR-10b was positively correlated with the positive expression of HER-2, the difference was statistically significant (P <0.05). The negative median tumor-free survival time of miR-10b expression was longer than that of miR-10b expression, with significant difference between the two (P <0.05). The median tumor-free survival time of negative miR-10b expression in miR- (P <0.05). On the contrary, the expression of miR-10b in lymph node-positive median tumor-free survival time was not statistically significant (P> 0.05). Conclusions The expression of miR-10b is correlated with the recurrence and metastasis of early invasive ductal carcinoma of breast, especially in the absence of lymph node metastasis and the median tumor-free survival time of miR-10b positive expression group is short with poor prognosis. The positive expression of miR-10b is a prognostic factor in early breast invasive ductal carcinoma.